Researchers found that Lilly’s investigational drug, retatrutide, has shown significant promise in helping people lose weight and improve health markers related to diabetes and cardiovascular disease. In two recent Phase 3 trials, participants with obesity and type 2 diabetes lost an average of nearly 50 pounds, while those with severe obesity and cardiovascular issues lost over 55 pounds after 80 weeks of treatment. These results indicate that retatrutide could be a valuable tool for managing weight and associated health risks in adults facing these challenges.

This is particularly relevant for individuals looking to maintain a healthy weight as they age, especially those with type 2 diabetes or cardiovascular concerns. The substantial weight loss observed—up to 22.6% in some participants—can lead to improved blood sugar levels and reduced cardiovascular risks. For those struggling with obesity, this treatment could mean a new way to enhance overall health and longevity.

The evidence comes from two large Phase 3 trials, TRIUMPH-2 and TRIUMPH-3, involving over 3,000 participants in total. While these results are promising, retatrutide is still in the investigational stage, meaning it has not yet been approved for general use. The studies reported generally mild to moderate side effects, such as gastrointestinal issues, which are common with weight-loss medications. More detailed findings will be shared at upcoming medical meetings and published in peer-reviewed journals, allowing for further evaluation of its safety and efficacy.

If you’re interested in weight management and improving your health, it may be worthwhile to discuss with your healthcare provider about emerging treatments like retatrutide and how they could fit into your overall wellness strategy.

For more information, see the original details from Lilly’s investor news.